A shadow market for unapproved slimming medications is being driven by TikTok fitness influencers and vendors on messaging platforms, based on new investigations.
Experimental Drug Gaining Popularity Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Viewers are urged to message these accounts privately for source information, while also receiving discount codes.
Thriving Commerce on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with numerous of participants share comparison photos, administration instructions and claims of next-day UK delivery. Vendors promote the drug there before directing customers to other platforms for transactions.
Understanding Retatrutide
This medication is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.
Healthcare Experts Voice Worries
Nevertheless, physicians and chemists have warned that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could lead to users administering substances of uncertain source.
Several professionals said the demand for the experimental drug could be connected to the rising cost of licensed slimming treatments such as Mounjaro.
Regulatory Position and Enforcement
Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unlicensed drug that cannot be marketed or distributed for personal consumption under the British medical regulations.
Some influencers try to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still breach pharmaceutical, advertising, and customer regulations, potentially leading to penalties, prosecution or imprisonment.
Service Response and Content Elimination
Based on the social media company, the service has removed problematic content and prohibited associated hashtags and query recommendations. The company stated it was dedicated to keeping the platform secure and allocating resources in strengthening enforcement strategies.
Digital Marketplace Activities
Investigations also discovered communities with up to 9,000 members marketing the experimental drug using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly displays groups with thousands of members, filled with images of slimming results, positive reviews and detailed guides for mixing or administering at home.
Within moments of joining one group, a seller shared contact information, where most purchases occur. The vendor sent an guidebook and guaranteed shipping within two days. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one inquired about body mass, medical conditions or past usage.
Product Details and Costs
Within these communities, messages show black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can select between dry substance containers, prepared at home with sterile water, or ready-to-use injectors usually priced at £160 for 20mg. When asked how long a pen should be used, vendors give contradictory responses varying between a several days to “depends on your body”.
Platform Oversight and Safety Actions
A spokesperson for Telegram said it actively moderated harmful material on its service including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering materials they can’t verify. Although the research behind this drug is sound, these online products may not include what they advertise,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor connected the increase in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using social media. But fake injections are extremely risky. You cannot know what’s inside or whether the environment they were made in was clean,” she said.
Her team has already encountered individuals injured by self-injection from unverified suppliers. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is taking chances with your health,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Statement
A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company experimental substance not yet approved … may subject users to possibly significant medical dangers”.
